Oncocyte Corp Stock Buy Hold or Sell Recommendation
| OCX Stock | USD 2.44 0.09 3.56% |
Considering the 90-day investment horizon and your complete indifference towards market risk, our recommendation regarding OncoCyte Corp is 'Strong Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell OncoCyte Corp given historical horizon and risk tolerance towards OncoCyte Corp. When Macroaxis issues a 'buy' or 'sell' recommendation for OncoCyte Corp, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out OncoCyte Corp Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide. In addition, we conduct extensive research on individual companies such as OncoCyte and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards OncoCyte Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
OncoCyte |
Execute OncoCyte Corp Buy or Sell Advice
The OncoCyte recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on OncoCyte Corp. Macroaxis does not own or have any residual interests in OncoCyte Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute OncoCyte Corp's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
OncoCyte Corp Trading Alerts and Improvement Suggestions
| OncoCyte Corp generated a negative expected return over the last 90 days | |
| OncoCyte Corp has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 1.5 M. Reported Net Loss for the year was (27.78 M) with profit before taxes, overhead, and interest of 188 K. | |
| OncoCyte Corp has about 45.41 M in cash with (23.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 16.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: StockNews.com Initiates Coverage on OncoCyte |
OncoCyte Corp Returns Distribution Density
The distribution of OncoCyte Corp's historical returns is an attempt to chart the uncertainty of OncoCyte Corp's future price movements. The chart of the probability distribution of OncoCyte Corp daily returns describes the distribution of returns around its average expected value. We use OncoCyte Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of OncoCyte Corp returns is essential to provide solid investment advice for OncoCyte Corp.
| Mean Return | -0.27 | Value At Risk | -4.76 | Potential Upside | 4.59 | Standard Deviation | 3.11 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of OncoCyte Corp historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
OncoCyte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as OncoCyte Corp, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading OncoCyte Corp back and forth among themselves.
| Shares | Tower Research Capital Llc | 2024-06-30 | 3.1 K | Advisor Group Holdings, Inc. | 2024-06-30 | 1.1 K | Ubs Group Ag | 2024-06-30 | 835 | Bank Of America Corp | 2024-06-30 | 416 | Jpmorgan Chase & Co | 2024-06-30 | 154 | Piscataqua Savings Bank | 2024-09-30 | 25.0 | Coppell Advisory Solutions Llc | 2024-06-30 | 10.0 | Albion Financial Group (utah) | 2024-06-30 | 7.0 | Td Waterhouse Canada Inc | 2024-06-30 | 1.0 | Broadwood Capital Inc | 2024-09-30 | 4.9 M | Awm Investment Company Inc | 2024-09-30 | 1.1 M |
OncoCyte Corp Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 15.7M | (14.9M) | 28.5M | (14.1M) | (12.1M) | (11.5M) | |
| Free Cash Flow | (20.6M) | (27.2M) | (38.2M) | (49.9M) | (23.6M) | (24.8M) | |
| Depreciation | 351K | 1.9M | 4.2M | 5.2M | 1.7M | 1.6M | |
| Other Non Cash Items | 437K | (2.2M) | 28.6M | 14.0M | 174K | 165.3K | |
| Capital Expenditures | 918K | 1.2M | 2.2M | 4.3M | 281K | 267.0K | |
| Net Income | (22.4M) | (29.9M) | (64.1M) | (72.9M) | (27.8M) | (29.2M) | |
| End Period Cash Flow | 23.8M | 8.8M | 37.3M | 23.2M | 11.1M | 13.8M | |
| Investments | (11.2M) | (4M) | (14.0M) | (4.3M) | (932K) | (978.6K) | |
| Net Borrowings | 2.3M | 695K | (1.5M) | (1.3M) | (1.2M) | (1.1M) | |
| Change To Netincome | 3.8M | 1.5M | 23.7M | 24.0M | 27.7M | 29.0M |
OncoCyte Corp Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to OncoCyte Corp or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that OncoCyte Corp's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a OncoCyte stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.28 | |
β | Beta against Dow Jones | 0.01 | |
σ | Overall volatility | 3.12 | |
Ir | Information ratio | -0.13 |
OncoCyte Corp Volatility Alert
OncoCyte Corp exhibits very low volatility with skewness of 0.84 and kurtosis of 2.28. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure OncoCyte Corp's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact OncoCyte Corp's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.OncoCyte Corp Fundamentals Vs Peers
Comparing OncoCyte Corp's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze OncoCyte Corp's direct or indirect competition across all of the common fundamentals between OncoCyte Corp and the related equities. This way, we can detect undervalued stocks with similar characteristics as OncoCyte Corp or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of OncoCyte Corp's fundamental indicators could also be used in its relative valuation, which is a method of valuing OncoCyte Corp by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare OncoCyte Corp to competition |
| Fundamentals | OncoCyte Corp | Peer Average |
| Return On Equity | -1.65 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Operating Margin | (55.43) % | (5.51) % |
| Current Valuation | 43.22 M | 16.62 B |
| Shares Outstanding | 16.84 M | 571.82 M |
| Shares Owned By Insiders | 15.95 % | 10.09 % |
| Shares Owned By Institutions | 50.58 % | 39.21 % |
| Number Of Shares Shorted | 194.19 K | 4.71 M |
| Price To Earning | (12.20) X | 28.72 X |
| Price To Book | 4.39 X | 9.51 X |
| Price To Sales | 60.07 X | 11.42 X |
| Revenue | 1.5 M | 9.43 B |
| Gross Profit | 188 K | 27.38 B |
| EBITDA | (23.12 M) | 3.9 B |
| Net Income | (27.78 M) | 570.98 M |
| Cash And Equivalents | 45.41 M | 2.7 B |
| Cash Per Share | 0.38 X | 5.01 X |
| Total Debt | 2.87 M | 5.32 B |
| Debt To Equity | 0.05 % | 48.70 % |
| Current Ratio | 3.49 X | 2.16 X |
| Book Value Per Share | 0.71 X | 1.93 K |
| Cash Flow From Operations | (23.32 M) | 971.22 M |
| Short Ratio | 3.80 X | 4.00 X |
| Earnings Per Share | (4.44) X | 3.12 X |
| Target Price | 4.25 | |
| Number Of Employees | 43 | 18.84 K |
| Beta | 1.0 | -0.15 |
| Market Capitalization | 42.59 M | 19.03 B |
| Total Asset | 74.89 M | 29.47 B |
| Retained Earnings | (289.88 M) | 9.33 B |
| Working Capital | 3.5 M | 1.48 B |
| Current Asset | 15.28 M | 9.34 B |
| Current Liabilities | 3.97 M | 7.9 B |
Note: Disposition of 3564728 shares by Gutfreund John Peter of OncoCyte Corp at 1.53 subject to Rule 16b-3 [view details]
OncoCyte Corp Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as OncoCyte . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About OncoCyte Corp Buy or Sell Advice
When is the right time to buy or sell OncoCyte Corp? Buying financial instruments such as OncoCyte Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having OncoCyte Corp in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hotels Thematic Idea Now
Hotels
Hotels, inns, motels, and other companies providing lodging and hospitality services. The Hotels theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hotels Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.